Article Link: FDA Approves Ofev (nintedanib) as First Treatment for Chronic Fibrosing Interstitial Lung Diseases (ILDs) with a Progressive Phenotype&#...
FDA Approves Isturisa (osilodrostat) for the Treatment of Cushing’s Disease
Article Link: FDA Approves Isturisa (osilodrostat) for the Treatment of Cushing’s Disease March 06, 2020 — The U.S. Food and Drug A...
FDA Approves Durysta (bimatoprost implant) to Lower Intraocular Pressure In Open-Angle Glaucoma or Ocular Hypertension Patients
Article Link: FDA Approves Durysta (bimatoprost implant) to Lower Intraocular Pressure In Open-Angle Glaucoma or Ocular Hypertension Patients &#...
FDA Approves Sarclisa (isatuximab-irfc) for Patients with Relapsed Refractory Multiple Myeloma
Article Link: FDA Approves Sarclisa (isatuximab-irfc) for Patients with Relapsed Refractory Multiple Myeloma BRIDGEWATER, N.J., March 2, ...
FDA Approves Advil Dual Action (ibuprofen and acetaminophen) as an Over-the-Counter Pain Treatment
Article Link: FDA Approves Advil Dual Action (ibuprofen and acetaminophen) as an Over-the-Counter Pain Treatment WARREN, N.J., Feb. 28, 2...
FDA Approves Nurtec ODT (rimegepant) for the Acute Treatment of Migraine in Adults
Article Link: FDA Approves Nurtec ODT (rimegepant) for the Acute Treatment of Migraine in Adults NEW HAVEN, Conn., Feb. 27, 2020 /PRNewsw...
FDA Approves Barhemsys (amisulpride) for the Treatment and Prevention of PONV
Article Link: FDA Approves Barhemsys (amisulpride) for the Treatment and Prevention of PONV Cambridge, UK and Indianapolis, US – 27 Febru...
FDA Approves Barhemsys (amisulpride) for the Treatment and Prevention of Postoperative Nausea and Vomiting
Article Link: FDA Approves Barhemsys (amisulpride) for the Treatment and Prevention of Postoperative Nausea and Vomiting Cambridge, UK an...
FDA Approves Nexlizet (bempedoic acid and ezetimibe) to Lower LDL-Cholesterol
Article Link: FDA Approves Nexlizet (bempedoic acid and ezetimibe) to Lower LDL-Cholesterol ANN ARBOR, Mich., Feb. 26, 2020 (GLOBE NEWSWI...
Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Article Link: Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breas...
